High frequency and reduced penetrance of lRRK2 g2019S mutation among Parkinson's disease patients in Cantabria (Spain)

Movement Disorders

Volumn 26, Issue 13, 2011, Pages 2343-2346

  Sierra, María ^a   González Aramburu, Isabel ^a   Sánchez Juan, Pascual ^a,b   Sánchez Quintana, Coro ^a,b   Polo, José Miguel ^a   Berciano, José ^a,b   Combarros, Onofre ^a,b   Infante, Jon ^a,b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

G2019S; LRRK2; Parkinson's disease; Penetrance

Indexed keywords

LEUCINE RICH REPEAT KINASE 2;

ADULT; AGED; ARAB; ARTICLE; DISEASE COURSE; FEMALE; GENE MUTATION; GENETIC RISK; HUMAN; INCIDENCE; JEW; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; OUTPATIENT CARE; PARKINSON DISEASE; PENETRANCE; PRIORITY JOURNAL; SPAIN; TERTIARY HEALTH CARE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PENETRANCE; POINT MUTATION; PROTEIN-SERINE-THREONINE KINASES; SPAIN;

EID: 81955167499     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23965     Document Type: Article

References (22)

1. Dächsel JC, Farrer MJ. LRRK2 and Parkinson disease. Arch Neurol 2010; 67: 542-547.
2. Correia Guedes L, Ferreira JJ, Rosa MM, Coelho M, Bonifati V, Sampaio C. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2010; 16: 237-242.
3. Thaler A, Ash E, Gan-Or Z, Orr-Urtreger A, Giladi N. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. J Neural Transm 2009; 116: 1473-1482.
4. Zabetian CP, Hutter CM, Yearout D, et al. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 2006; 79: 752-758.
5. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005; 76: 672-680.
6. Lesage S, Ibanez P, Lohmann E, et al. French Parkinson's Disease Genetics Study Group. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005; 58: 784-787.
7. Healy DG, Falchi M, O'sullivan SS, et al. International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7: 583-590.
8. Latourelle JC, Sun M, Lew MF, et al. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med 2008; 6: 32.
9. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006; 354: 424-425.
10. Clark LN, Wang Y, Karlins E, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 2006; 67: 1786-1791.
11. Goldwurm S, Zini M, Mariani L, et al. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology 2007; 68: 1141-1143.
12. Troiano AR, Elbaz A, Lohmann E, et al. French Parkinson Disease Genetic Study Group. Low disease risk in relatives of North African LRRK2 Parkinson disease patients. Neurology 2010; 75: 1118-1119.
13. Infante J, Rodríguez E, Combarros O, et al. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. Neurosci Lett 2006; 395: 224-226.
14. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857-872.
15. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927; 22: 209-212.
16. Gaig C, Ezquerra M, Marti MJ, Muñoz E, Valldeoriola F, Tolosa E. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 2006; 63: 377-382.
17. Mata IF, Ross OA, Kachergus J, et al. LRRK2 mutations are a common cause of Parkinson's disease in Spain. Eur J Neurol 2006; 4: 391-394.
18. Gorostidi A, Ruiz-Martínez J, Lopez de Munain A, Alzualde A, Massó JF. LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 2009; 10: 157-159.
19. Gao L, Gómez-Garre P, Díaz-Corrales FJ, et al. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain. Eur J Neurol 2009; 16: 957-960.
20. Morán JM, Castellanos-Pinedo F, Casado-Naranjo I, et al. Genetic screening for the LRRK2, G2019S and R1441 codon mutations in Parkinson's disease patients from Extremadura, Spain. Rev Neurol 2010; 50: 591-594.
21. Ferreira JJ, Guedes LC, Rosa MM, et al. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. Mov Disord 2007; 22: 1194-1201.
22. Healy DG, Wood NW, Schapira AH. Test for LRRK2 mutations in patients with Parkinson's disease. Pract Neurol 2008; 8: 381-385.